BiotechTube
Melinta Therapeutics

Melinta Therapeutics

Parsippany, United States· Est.
melinta.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $540M

Overview

Melinta Therapeutics is a commercial-stage antibiotic company confronting the global public health threat of antimicrobial resistance (AMR). Founded in 2000, the company has navigated significant financial challenges, including a Chapter 11 restructuring in 2019, to maintain a portfolio of vital anti-infective agents. Its strategy centers on commercializing its approved products—BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCYCLINE Injection, and VABOMERE (meropenem and vaborbactam)—while advancing its pipeline. The company operates in a high-need but commercially difficult market, reliant on strategic partnerships and public health initiatives for sustainable success.

Infectious DiseaseAntimicrobial Resistance

Technology Platform

Portfolio of small molecule antibiotics with distinct mechanisms of action (fluoroquinolone, lipoglycopeptide, beta-lactam/beta-lactamase inhibitor) targeting resistant gram-positive and gram-negative bacteria.

Funding History

4
Total raised:$540M
PIPE$135M
Debt$200M
Series B$135M
Series A$70M

Opportunities

The urgent global threat of antimicrobial resistance creates a critical need for novel antibiotics like Melinta's portfolio.
Evolving market access models, such as the proposed U.S.
PASTEUR Act, could provide stable, subscription-based revenue, transforming the business case for antibiotic developers.
Strategic partnerships with larger pharmaceutical companies or government entities could provide non-dilutive funding and expanded commercial reach.

Risk Factors

The primary risk is the broken antibiotic market, where low usage (to preserve efficacy) conflicts with traditional volume-based revenue models, threatening commercial sustainability.
The company operates with likely limited financial resources and a narrow margin for error, making it vulnerable to sales fluctuations or unexpected costs.
Competition from other novel antibiotics and generic alternatives creates ongoing pricing and market share pressure.

Competitive Landscape

Melinta competes in the niche but competitive market for novel antibiotics against companies like Paratek Pharmaceuticals (NUZYRA), Nabriva Therapeutics (now part of Advanz Pharma), and innovators such as Entasis Therapeutics (sulbactam-durlobactam) and Venatorx Pharmaceuticals (cefepime-taniborbactam). It also faces indirect competition from generic antibiotics and the R&D pipelines of larger pharma companies with antibiotic divisions, such as Pfizer and Merck.

More companies in Small Molecule Drugs →More companies in United States →